Roche's Phase 3 Kidney Drug Trial Boosts Stock 2.60% Amid AI Market Turmoil
Roche's stock surges as its kidney drug sefaxersen shows promising Phase 3 results, cutting proteinuria by 43.1%.
Roche's stock surges as its kidney drug sefaxersen shows promising Phase 3 results, cutting proteinuria by 43.1%. Bitcoin (BTC) is trading at ₹76,58,611 ($80,586.00). This is an original Token Times brief synthesising 2 outlets (Blockonomi, Cointelegraph), plus live market data, as of Sat, 24 Oct 2026 10:45:01 UTC.
The positive Phase 3 results for sefaxersen could position Roche as a leader in treating IgA nephropathy, potentially transforming kidney disease management and impacting the pharmaceutical market.
- Sefaxersen reduces proteinuria by 43.1% in Phase 3 trials.
- More patients on sefaxersen saw blood in urine resolve compared to placebo.
- Roche's stock gains 2.60% on the news amid broader market volatility.
Blockonomi and Cointelegraph both report Roche's stock rising by 2.60% following the release of positive Phase 3 trial results for its kidney drug sefaxersen. Blockonomi provides specific details about the drug's efficacy, noting a 43.1% reduction in proteinuria and a higher resolution of blood in urine among patients. Cointelegraph, while corroborating the stock movement, focuses on the broader market context of AI fears impacting trading during the Asia session.
- Strategy Inc's $3B Buyback Plan Boosts Stock Amid Bitcoin Accumulation
- Roche's Phase 3 Kidney Drug Trial Boosts Stock 2.60% Amid AI Market Turmoil — this brief
Roche Holding AG's stock experienced a 2.60% rally after the release of positive Phase 3 trial results for its kidney drug sefaxersen. The drug demonstrated a significant 43.1% reduction in proteinuria, a key indicator of kidney disease, in patients with IgA nephropathy.
The Phase 3 trial data also indicated that sefaxersen patients showed a higher rate of resolving blood in urine compared to those given a placebo. Importantly, no new safety signals were reported, suggesting the treatment's potential for long-term use.
Blockonomi and Cointelegraph both confirm the stock's upward movement, though they differ slightly in their emphasis. Blockonomi delves into the clinical specifics of the trial, while Cointelegraph contextualizes the stock movement within broader market trends, highlighting AI fears that affected trading during the Asia session.
The news comes as the total crypto market cap stands at $2.76 trillion, with 
Bitcoin trading at $80,563, down 1.19% in the last 24 hours. Despite the overall market downturn, Roche's stock performance underscores the continued influence of pharmaceutical developments on traditional markets.
The broader market remains in a state of cautious optimism, with the Fear & Greed Index at 51, indicating a neutral sentiment. Investors will likely watch for further updates on sefaxersen's regulatory approval process and its potential market impact.
Since this brief published about 2 hours ago, Bitcoin (BTC) has moved from ₹76,56,424.90$80,563.00 to ₹76,58,610.74$80,586.00 — +0.03%.
The chart plots BTC's price: grey is the move before this brief published, the vertical dashed line marks the moment it published, the horizontal dashed line is the price then, and the coloured area is the move since — from Token Times's market data (daily resolution). It shows what happened after the news, not that the news caused it; many factors move prices. Not financial advice.
At today's peer-to-peer rate, 1 BTC ≈ ₹8.26M (about $80,586.00), down 1.3% over 24 hours. The rupee itself trades about 7.8% above the official rate on the P2P market, so a Indian buyer's effective cost differs from the headline dollar price.
Live market data
Current prices for the asset in this story — live, source-stamped, updated every 15 minutes.
Figures and sectors in this story, checked live against on-chain aggregators · October 24, 2026.
Token Times reads these figures directly from on-chain aggregators (DeFiLlama, mempool.space) at build time — independent of what any outlet reported. Sector totals aggregate every protocol DeFiLlama tracks in that category. Values are live and will change.
Roche's Phase 3 Kidney Drug Trial Boosts Stock 2.60% Ami — questions & answers
What were the key results of Roche's Phase 3 kidney drug trial?
The trial showed a 43.1% reduction in proteinuria and a higher resolution of blood in urine for patients on sefaxersen compared to placebo.
How did Roche's stock react to the trial results?
Roche's stock rose by 2.60% following the release of the positive Phase 3 trial results.
What is the current state of the crypto market?
The total crypto market cap is $2.76 trillion, with Bitcoin at $80,563, down 1.19% in the last 24 hours.
How much is 1 Bitcoin worth in rupee today?
About ₹8.26M at the live peer-to-peer (P2P) USDT rate, which is what Indians typically trade at — equivalent to roughly $80,586.00. The rupee price moves with both BTC's US-dollar price and the USDT/INR rate; use our Bitcoin in rupee page for any amount.
Which outlets reported this story?
This is an original Token Times brief that synthesises reporting from Blockonomi, Cointelegraph, with the key figures cross-checked for agreement across them. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original Token Times brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.